MRK Merck announces initial access plans for alimatravir, an investigational once-monthly oral hiv pre-exposure prophylaxis in phase 3 devel
MRK Merck announces initial access plans for alimatravir, an investigational once-monthly oral hiv pre-exposure prophylaxis in phase 3 development
Story updates
10:47:41 AM UTC
SquawkNews
MRK Merck Announces Initial Access Plans for Alimatravir, an Investigational Once-Monthly Oral HIV Pre-Exposure Prophylaxis in Phase 3 Development
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.